Page last updated: 2024-08-18

pyrroles and Cancer of Ovary

pyrroles has been researched along with Cancer of Ovary in 57 studies

Research

Studies (57)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	2 (3.51)	18.2507
2000's	20 (35.09)	29.6817
2010's	30 (52.63)	24.3611
2020's	5 (8.77)	2.80

Authors

Authors	Studies
Blucher, A; Chelariu-Raicu, A; Chen, TH; Coleman, RL; Creason, A; Fang, Y; Fellman, B; Feng, N; Frumovitz, M; Jazaeri, A; Kabil, N; Kim, TB; Labrie, M; Lee, S; Litton, JK; Liu, J; Lu, KH; Ma, X; Marszalek, JR; Meyer, LA; Mills, GB; Murthy, R; Schmeler, KM; Soliman, PT; Sood, AK; Sun, CC; Vellano, CP; Westin, SN; Yuan, Y	1
Feng, Z; Gao, C; He, H; Li, X; Liu, Z; Ran, K; Shi, Y; Wang, N; Wei, W; Ye, T; Yu, L; Zhu, Y	1
Abdullah, N; Al Bahlani, S; Al Balushi, N; Burney, IA; Dobretsov, S; Hasan, SI; Tamimi, Y	1
Imae, T; Krathumkhet, N; Manidae Lumban Gaol, J; Paradee, N; Wang, FM; Yuan, CC	1
Brickman, D; Cristea, M; Fleming, GF; Fong, A; French, D; Hamilton, E; Moore, K; O'Cearbhaill, R; O'Malley, DM; Rossi, M; Tariq, B	1
Brady, W; Brown, J; Chan, JK; Gershenson, DM; Kim, JH; Monk, BJ; Rose, PG; Secord, AA; Shahin, MS; Walker, JL	1
Bonezzi, K; Borsotti, P; Cvitkovic, E; D'Incalci, M; Frapolli, R; Giavazzi, R; Noel, K; Sala, F; Taraboletti, G; Ubezio, P; Zangarini, M; Zucchetti, M	1
Ferrero, S; Leone Roberti Maggiore, U; Valenzano Menada, M; Venturini, PL	1
Becker, MA; Farzan, T; Haluska, P; Harrington, SC; Hou, X; Kalli, KR; Krempski, JW; Weroha, SJ; Wong, TW	1
Buchsbaum, DJ; Fauci, JM; Ferrone, S; Landen, CN; Londoño-Joshi, AI; Sabbatino, F; Straughn, JM; Wang, Y	1
Donahue, RN; Farsaci, B; Grenga, I; Gulley, JL; Jochems, C; Kim, PS; Schlom, J; Tsang, KY	1
Chang, MC; Chen, CA; Chen, TC; Chen, YL; Cheng, WF; Huang, CT	1
Griffioen, AW; Kilarski, WW; Nowak-Sliwinska, P; Sarna, T; Szewczyk, G; van Beijnum, JR; van den Bergh, H; Verheul, HM; Weiss, A; Wong, TJ	1
Arens, R; Melief, CJ; Sluijter, M; van der Burg, SH; van der Sluis, TC; van Duikeren, S; van Hall, T; West, BL	1
Gao, L; Gao, Y; Li, J; Shan, N; Wang, Y; Xu, F; Yi, Z; Yu, X; Zhao, C	1
Han, J; Hoff, BH; Kaspersen, SJ; Sundby, E	1
Kang, J; Li, H; Li, X; Ma, C; Ma, L; Su, J; Sun, L; Xia, M; Xu, Y; Yu, H; Zhang, Z	1
Chang, LL; Chen, Y; Chen, ZB; Wang, DD; Zhao, PG; Zhou, TY; Zhu, H	1
Alsina-Sanchis, E; Casanovas, O; Figueras, A; Graupera, M; Lahiguera, Á; Vidal, A; Villanueva, A; Viñals, F	1
Jackson, PJ; Mantaj, J; Rahman, KM; Thurston, DE	1
Amaravadi, RK; Anglesio, MS; DeVorkin, L; Hattersley, M; Huntsman, DG; Kim, P; Levi, SM; Lum, JJ; Ries, J; Spowart, J; Tinker, AV; Winkler, JD	1
Bischoff, J; Costa, SD; Ignatov, A; Smith, B; Taran, A	1
Kumar, S; Liang, SL; Liu, H; Liu, W; Weyman, CM; Zhou, A	1
Azzoli, CG; Calcutt, MW; Janjigian, YY; Kris, MG; Krug, LM; Lee, W; Miller, VA; Rizvi, NA; Senturk, E	1
Beyer, M; Classen, S; Debey-Pascher, S; Eggle, D; Kuhn, W; Lahn, M; Mallmann, MR; Muth, C; Pölcher, M; Rudlowski, C; Schultze, JL; Staratschek-Jox, A; Zander, T	1
Arias-Pulido, H; Brouwer-Visser, J; Goldberg, GL; Hebert, TM; Horwitz, SB; Huang, GS; Kim, CH; Lin, J; Prossnitz, ER; Qualls, CR; Ramirez, MJ; Smith, HO	1
Biagi, JJ; Chalchal, HI; Eisenhauer, EA; Ellard, SL; Grimshaw, R; Hirte, H; Ivy, SP; Lee, U; Oza, AM; Sederias, J	1
Bauerschlag, DO; Egberts, JH; Jonat, W; Kalthoff, H; Maass, N; Meinhold-Heerlein, I; Schem, C; Tiwari, S; Weigel, MT	1
Anglesio, MS; Balkwill, F; Birrer, MJ; Bowtell, DD; Campbell, IG; Chakravarty, P; Coward, J; Cowin, PA; de Fazio, A; Friedlander, M; George, J; Gilks, CB; Gorringe, KL; House, CM; Huntsman, DG; Kalloger, SE; Kulbe, H; Lemech, C; Okamoto, A; Power, J; Rischin, D	1
Boutros, PC; Clendening, JW; Goard, CA; Martirosyan, A; Mather, RG; Penn, LZ; Sharom, FJ; Vinepal, B	1
Chen, T; Ge, S; Guo, H; Hu, P; Li, X; Liu, Y; Nadkarni, DH; Velu, SE; Wang, H; Wang, W; Xu, Y; Yang, X; Zhang, R	1
Birrer, MJ; Bowtell, D; Ellard, SL; Gilks, CB; Gout, PW; Huntsman, DG; Kagami, T; Lopez-Berestein, G; McAlpine, JN; Miller, DM; Mok, SC; Ozbun, L; Sood, AK; Stany, MP; Stone, RL; Vathipadiekal, V; Vivas-Mejia, P; Wang, Y; Wang, YZ; Xue, H	1
Colon-Otero, G; Copland, JA; Kennedy, GT; Kennedy, WP; Marlow, LA; Santoso, JT; Vishnu, P; Wu, KJ	1
Bauerschlag, D; Baumann, KH; Canzler, U; Dewitz, T; du Bois, A; Hanker, LC; Hasenburg, A; Hillemanns, P; Hilpert, F; Kurzeder, C; Meier, W; Rau, J; Richter, B; Sehouli, J; Wagner, U; Wimberger, P; Wollschlaeger, K	1
Bansal, S; Kawsar, HI; Myles, JL	1
Kaczor, AA; Karczmarzyk, Z; Matosiuk, D; Pitucha, M; Rzymowska, J; Wysocki, W	1
Berlin, S; Campos, SM; Horowitz, NS; Matulonis, U; Penson, RT; Pereira, L; Roche, M; Szymonifka, J; Tyburski, K; Whalen, C	1
Ademefun, T; Cooper, N; Hagan, DR; Howard, PW; Matthews, CS; Thurston, DE; Tiberghien, A	1
Arencibia, JM; Bajo, AM; Chatzistamou, I; Krupa, M; Nagy, A; Schally, AV	1
Baselga, J; Hammond, LA	1
Li, QQ; Reed, E; Zhong, X	1
Caniatti, M; Cherrington, JM; Colombo, T; Garofalo, A; Ghilardi, C; Ghisleni, G; Giavazzi, R; Manenti, L; Naumova, E; Nicoletti, MI; Scanziani, E	1
Ding, H; Hu, G; Li, QQ; Li, X; Neace, C; Reed, E; Wang, G; Zhao, J; Zhong, X; Zhu, Y	1
Jiang, BH; Reed, E; Zheng, JZ; Zhong, XS	1
Kohno, T; Konno, R; Machida, S; Mizuno, I; Ohwada, M; Saga, Y; Suzuki, M; Takayama, T; Takei, Y	1
Nagy, A; Schally, AV	1
Blouin, MJ; Bruchim, I; Camirand, A; Gotlieb, WH; Gu, J; Pollak, MN; Shi, Y; Zhao, Y	1
Arrington, KL; Buser, CA; Coleman, PJ; Fernandes, C; Fraley, ME; Garbaccio, RM; Hamilton, K; Hartman, GD; Heimbrook, DC; Hoffman, WF; Huber, HE; Kohl, NE; Kuo, LC; Lobell, RB; Prueksaritanont, T; Schaber, MD; Shu, C; South, VJ; Tao, W; Tasber, ES; Torrent, M; Walsh, ES; Yan, Y	1
Auersperg, N; Cosin, J; Dings, RP; Ramakrishnan, S; Schumacher, JJ; Subramanian, IV	1
Alagkiozidis, I; Coukos, G; Gimotty, PA; Guo, W; Holtz, DO; Krafty, RT; Leiby, B; Mohamed-Hadley, A; Zhang, L	1
Baig, MA; Coffils, M; Hartley, JA; Howard, PW; Jenkins, TC; Loadman, PM; Suggitt, M; Thurston, DE; Wells, G	1
Barrows, LR; Copp, BR; Ireland, CM; Kramer, RA; Radisky, DC; Swaffar, DS; Warters, RL	1
Barcella, S; Corcoran, KE; Gregson, SJ; Howard, PW; Hurst, AA; Jenkins, TC; Kelland, LR; Thurston, DE; Yasin, MM	1
Barcella, S; Gregson, SJ; Howard, PW; Jenkins, TC; Kelland, LR; Nakamya, A; Thurston, DE	1
Arencibia, JM; Csernus, B; Halmos, G; Koppan, M; Nagy, A; Plonowski, A; Schally, AV	1
Battaglia, R; Broggini, M; Colombo, T; Cozzi, P; D'Incalci, M; Galliera, E; Geroni, C; Howard, M; Marchini, S; Ragg, E	1
Alberts, DS; Dorr, RT; Islam, I; Skibo, EB	1

Reviews

4 review(s) available for pyrroles and Cancer of Ovary

Article	Year
The potential of sunitinib as a therapy in ovarian cancer. Expert opinion on investigational drugs, 2013, Volume: 22, Issue:12 Topics: Adenocarcinoma, Clear Cell; Animals; Drug Approval; Drug Resistance, Neoplasm; Female; Humans; Indoles; Ovarian Neoplasms; Protein Kinase Inhibitors; Pyrroles; Sunitinib	2013
From Anthramycin to Pyrrolobenzodiazepine (PBD)-Containing Antibody-Drug Conjugates (ADCs). Angewandte Chemie (International ed. in English), 2017, 01-09, Volume: 56, Issue:2 Topics: Anthramycin; Antibiotics, Antineoplastic; Antibodies; Benzodiazepines; Cell Proliferation; Female; Humans; Leukemia; Molecular Structure; Ovarian Neoplasms; Pyrroles	2017
HER-targeted tyrosine-kinase inhibitors. Oncology, 2002, Volume: 63 Suppl 1 Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Morpholines; Ovarian Neoplasms; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Quinazolines; Receptor, ErbB-2	2002
Targeting of cytotoxic luteinizing hormone-releasing hormone analogs to breast, ovarian, endometrial, and prostate cancers. Biology of reproduction, 2005, Volume: 73, Issue:5 Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Doxorubicin; Endometrial Neoplasms; Epithelial Cells; Female; Gonadotropin-Releasing Hormone; Humans; Male; Ovarian Neoplasms; Prostatic Neoplasms; Pyrroles; Receptors, LHRH	2005

Trials

8 trial(s) available for pyrroles and Cancer of Ovary

Article	Year
Phase Ib Dose Expansion and Translational Analyses of Olaparib in Combination with Capivasertib in Recurrent Endometrial, Triple-Negative Breast, and Ovarian Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2021, 12-01, Volume: 27, Issue:23 Topics: Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Ovarian Neoplasms; Phthalazines; Piperazines; Pyrimidines; Pyrroles; Triple Negative Breast Neoplasms	2021
Tamrintamab pamozirine (SC-003) in patients with platinum-resistant/refractory ovarian cancer: Findings of a phase 1 study. Gynecologic oncology, 2020, Volume: 158, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Benzodiazepines; Carcinoma, Ovarian Epithelial; Dipeptidases; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Immunoconjugates; Middle Aged; Molecular Targeted Therapy; Ovarian Neoplasms; Pyrroles	2020
A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254). Gynecologic oncology, 2018, Volume: 150, Issue:2 Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Angiogenesis Inhibitors; Carcinoma, Ovarian Epithelial; Female; Humans; Indoles; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Pyrroles; Sunitinib; Young Adult	2018
A phase I trial of SJG-136 (NSC#694501) in advanced solid tumors. Cancer chemotherapy and pharmacology, 2010, Volume: 65, Issue:5 Topics: Aged; Antineoplastic Agents; Benzodiazepinones; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Tolerance; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Ovarian Neoplasms; Pyrroles; Urinary Bladder Neoplasms	2010
A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study. Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Volume: 22, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; CA-125 Antigen; Disease Progression; Female; Humans; Indoles; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms; Pyrroles; Recurrence; Sunitinib; Survival Analysis	2011
IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Apr-15, Volume: 17, Issue:8 Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Angiogenesis Inhibitors; Cell Line, Tumor; Cluster Analysis; Drug Resistance, Neoplasm; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Indoles; Interleukin-6; Middle Aged; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Pyrroles; Signal Transduction; STAT3 Transcription Factor; Sunitinib; Tissue Array Analysis; Treatment Outcome	2011
A phase II trial (AGO 2.11) in platinum-resistant ovarian cancer: a randomized multicenter trial with sunitinib (SU11248) to evaluate dosage, schedule, tolerability, toxicity and effectiveness of a multitargeted receptor tyrosine kinase inhibitor monother Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:9 Topics: Angiogenesis Inhibitors; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Indoles; Kaplan-Meier Estimate; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Platinum Compounds; Proportional Hazards Models; Pyrroles; Receptor Protein-Tyrosine Kinases; Sunitinib	2012
A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma. Gynecologic oncology, 2013, Volume: 128, Issue:2 Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Disease-Free Survival; Drug Administration Schedule; Fallopian Tube Neoplasms; Female; Humans; Indoles; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Peritoneal Neoplasms; Protein Kinase Inhibitors; Pyrroles; Sunitinib	2013

Other Studies

45 other study(ies) available for pyrroles and Cancer of Ovary

Article	Year
Design, synthesis and biological evaluation of 7-((7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)-2,3-dihydro-1H-inden-1-one derivatives as potent FAK inhibitors for the treatment of ovarian cancer. European journal of medicinal chemistry, 2022, Jan-15, Volume: 228 Topics: Animals; Antineoplastic Agents; Dose-Response Relationship, Drug; Drug Design; Drug Screening Assays, Antitumor; Female; Focal Adhesion Kinase 1; Humans; Indans; Mice; Mice, Inbred BALB C; Mice, Nude; Microsomes, Liver; Molecular Structure; Neoplasms, Experimental; Ovarian Neoplasms; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Structure-Activity Relationship; Tumor Cells, Cultured	2022
Hymenialdisine is Cytotoxic Against Cisplatin-Sensitive but Not Against Cisplatin-Resistant Cell Lines. Sultan Qaboos University medical journal, 2021, Volume: 21, Issue:4 Topics: Azepines; Cell Line, Tumor; Cisplatin; Drug Resistance, Neoplasm; Humans; Ovarian Neoplasms; Pyrroles	2021
Electrochemical immunosensing by carbon ink/carbon dot/ZnO-labeled-Ag@polypyrrole composite biomarker for CA-125 ovarian cancer detection. Bioelectrochemistry (Amsterdam, Netherlands), 2023, Volume: 152 Topics: Biosensing Techniques; CA-125 Antigen; Carbon; Electrochemical Techniques; Female; Humans; Immunoassay; Ink; Limit of Detection; Metal Nanoparticles; Ovarian Neoplasms; Polymers; Pyrroles; Zinc Oxide	2023
Pharmacokinetics and antineoplastic activity of galectin-1-targeting OTX008 in combination with sunitinib. Cancer chemotherapy and pharmacology, 2013, Volume: 72, Issue:4 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Calixarenes; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Endothelial Cells; Female; Galectin 1; Glioblastoma; Half-Life; Humans; Indoles; Inhibitory Concentration 50; Mice; Mice, Nude; Molecular Targeted Therapy; Ovarian Neoplasms; Pyrroles; Sunitinib; Tissue Distribution; Xenograft Model Antitumor Assays	2013
Dual HER/VEGF receptor targeting inhibits in vivo ovarian cancer tumor growth. Molecular cancer therapeutics, 2013, Volume: 12, Issue:12 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cluster Analysis; Disease Models, Animal; Disease Progression; Female; Humans; Mice; Neoplasm Grading; Ovarian Neoplasms; Piperidines; Protein Kinase Inhibitors; Proteomics; Pyrroles; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Triazines; Tumor Burden; Xenograft Model Antitumor Assays	2013
Monoclonal antibody-based immunotherapy of ovarian cancer: targeting ovarian cancer cells with the B7-H3-specific mAb 376.96. Gynecologic oncology, 2014, Volume: 132, Issue:1 Topics: Antibodies, Monoclonal; B7 Antigens; Cell Proliferation; Drug Resistance, Neoplasm; Epitopes; Female; Humans; Indoles; Neoplastic Stem Cells; Ovarian Neoplasms; Pyrroles; Sunitinib	2014
Pan-Bcl-2 inhibitor, GX15-070 (obatoclax), decreases human T regulatory lymphocytes while preserving effector T lymphocytes: a rationale for its use in combination immunotherapy. Journal of immunology (Baltimore, Md. : 1950), 2014, Mar-15, Volume: 192, Issue:6 Topics: Apoptosis; Cells, Cultured; Combined Modality Therapy; CTLA-4 Antigen; Dose-Response Relationship, Drug; Down-Regulation; Female; Flow Cytometry; Forkhead Transcription Factors; Humans; Immunotherapy; Indoles; Leukocytes, Mononuclear; Lymphocyte Activation; Ovarian Neoplasms; Proto-Oncogene Proteins c-bcl-2; Pyrroles; T-Lymphocyte Subsets; T-Lymphocytes, Regulatory; Time Factors	2014
Insulin-like growth factors inhibit dendritic cell-mediated anti-tumor immunity through regulating ERK1/2 phosphorylation and p38 dephosphorylation. Cancer letters, 2015, Apr-01, Volume: 359, Issue:1 Topics: Animals; Antineoplastic Agents; Ascites; Cell Line, Tumor; Coculture Techniques; Dendritic Cells; Female; Humans; Immunity, Cellular; Insulin-Like Growth Factor I; Insulin-Like Growth Factor II; Interferon-gamma; Interleukins; Lymphocyte Activation; Mice, Inbred C57BL; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Neoplasm Staging; Ovarian Neoplasms; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Pyrimidines; Pyrroles; Receptor, IGF Type 1; Signal Transduction; T-Lymphocytes, Cytotoxic; Time Factors; Transfection; Tumor Necrosis Factor-alpha	2015
Photoactivation of lysosomally sequestered sunitinib after angiostatic treatment causes vascular occlusion and enhances tumor growth inhibition. Cell death & disease, 2015, Feb-12, Volume: 6 Topics: Animals; Cell Line, Tumor; Chickens; Colorectal Neoplasms; Female; Human Umbilical Vein Endothelial Cells; Humans; Immunohistochemistry; Indoles; Lysosomes; Mice; Mice, Inbred BALB C; Ovarian Neoplasms; Phototherapy; Pyrroles; Sunitinib	2015
Therapeutic Peptide Vaccine-Induced CD8 T Cells Strongly Modulate Intratumoral Macrophages Required for Tumor Regression. Cancer immunology research, 2015, Volume: 3, Issue:9 Topics: Aminopyridines; Animals; Cancer Vaccines; CD8-Positive T-Lymphocytes; Cell Movement; Chemokines; Disease Models, Animal; Female; Lymphocytes, Tumor-Infiltrating; Macrophages; Mice, Inbred C57BL; Myeloid Cells; Ovarian Neoplasms; Protein-Tyrosine Kinases; Pyrroles; Vaccines, Subunit	2015
LY2109761 enhances cisplatin antitumor activity in ovarian cancer cells. International journal of clinical and experimental pathology, 2015, Volume: 8, Issue:5 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Cell Proliferation; Cell Survival; Cisplatin; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Mice, Inbred ICR; Mice, SCID; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrazoles; Pyrroles; Receptor, Transforming Growth Factor-beta Type I; Receptor, Transforming Growth Factor-beta Type II; Receptors, Transforming Growth Factor beta; Signal Transduction; Smad2 Protein; Time Factors; Transforming Growth Factor beta; Tumor Burden; Xenograft Model Antitumor Assays	2015
In vitro baselining of new pyrrolopyrimidine EGFR-TK inhibitors with Erlotinib. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2015, Dec-01, Volume: 80 Topics: Antineoplastic Agents; Breast Neoplasms; Caco-2 Cells; Cell Line, Tumor; Cell Proliferation; Cytochrome P-450 Enzyme Inhibitors; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; In Vitro Techniques; Lung Neoplasms; Ovarian Neoplasms; Pyrimidines; Pyrroles	2015
Caspase-mediated cleavage of Beclin1 inhibits autophagy and promotes apoptosis induced by S1 in human ovarian cancer SKOV3 cells. Apoptosis : an international journal on programmed cell death, 2016, Volume: 21, Issue:2 Topics: Acenaphthenes; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Beclin-1; Caspase 3; Cell Line, Tumor; Cell Survival; Drug Screening Assays, Antitumor; Female; Humans; Membrane Proteins; Ovarian Neoplasms; Proteolysis; Pyrroles	2016
[Sunitinib suppresses migration of ovarian cancer cells through negative modulation of TGF-β-mediated epithelial-mesenchymal transition]. Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences, 2015, Volume: 44, Issue:5 Topics: Antigens, CD; Cadherins; Cell Line, Tumor; Cell Movement; Down-Regulation; Epithelial-Mesenchymal Transition; Female; Humans; Indoles; Ovarian Neoplasms; Pyrroles; Smad Proteins; Snail Family Transcription Factors; Sunitinib; Transcription Factors; Transforming Growth Factor beta; Up-Regulation	2015
The TGFβ pathway stimulates ovarian cancer cell proliferation by increasing IGF1R levels. International journal of cancer, 2016, 10-15, Volume: 139, Issue:8 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Carcinoma, Ovarian Epithelial; Cell Proliferation; Female; Heterografts; Humans; Mice; Mice, Nude; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Pyrazoles; Pyrroles; Random Allocation; Receptor, IGF Type 1; Receptors, Somatomedin; Signal Transduction; Transforming Growth Factor beta	2016
Autophagy Inhibition Enhances Sunitinib Efficacy in Clear Cell Ovarian Carcinoma. Molecular cancer research : MCR, 2017, Volume: 15, Issue:3 Topics: Adenocarcinoma, Clear Cell; Aminoquinolines; Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Female; Humans; Indoles; Mice; Mice, Inbred NOD; Mice, SCID; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Polyamines; Pyrroles; Sunitinib; Xenograft Model Antitumor Assays	2017
Acute hepatic failure following monotherapy with sunitinib for ovarian cancer. Cancer chemotherapy and pharmacology, 2009, Volume: 63, Issue:5 Topics: Antineoplastic Agents; Fatal Outcome; Female; Humans; Indoles; Liver Failure, Acute; Lymphatic Metastasis; Middle Aged; Ovarian Neoplasms; Pyrroles; Sunitinib	2009
Statins induce apoptosis in ovarian cancer cells through activation of JNK and enhancement of Bim expression. Cancer chemotherapy and pharmacology, 2009, Volume: 63, Issue:6 Topics: Apoptosis; Apoptosis Regulatory Proteins; Atorvastatin; Bcl-2-Like Protein 11; cdc42 GTP-Binding Protein; Cell Culture Techniques; Cell Line, Tumor; Cell Survival; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; JNK Mitogen-Activated Protein Kinases; Lovastatin; Membrane Proteins; Ovarian Neoplasms; Proto-Oncogene Proteins; Pyrroles; rac1 GTP-Binding Protein	2009
Application of T cell-based transcriptomics to identify three candidate biomarkers for monitoring anti-TGFbetaR therapy. Pharmacogenetics and genomics, 2010, Volume: 20, Issue:3 Topics: Biomarkers; Breast Neoplasms; Cells, Cultured; Dose-Response Relationship, Drug; Female; Gene Expression Profiling; Gene Expression Regulation; Humans; Male; Monitoring, Physiologic; Oligonucleotide Array Sequence Analysis; Ovarian Neoplasms; Prostatic Neoplasms; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Pyrazoles; Pyrroles; Receptor, Transforming Growth Factor-beta Type I; Receptors, Transforming Growth Factor beta; T-Lymphocytes; Transcription, Genetic	2010
Insulin-like growth factor 2 expression modulates Taxol resistance and is a candidate biomarker for reduced disease-free survival in ovarian cancer. Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Jun-01, Volume: 16, Issue:11 Topics: Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Gene Knockdown Techniques; Humans; Insulin-Like Growth Factor II; Ovarian Neoplasms; Paclitaxel; Phosphorylation; Prognosis; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Receptor, IGF Type 1; RNA, Small Interfering; Signal Transduction	2010
Sunitinib (SU11248) inhibits growth of human ovarian cancer in xenografted mice. Anticancer research, 2010, Volume: 30, Issue:9 Topics: Animals; Antineoplastic Agents; Disease Progression; Female; Humans; Immunohistochemistry; Indoles; Mice; Mice, SCID; Neovascularization, Pathologic; Ovarian Neoplasms; Pyrroles; Sunitinib; Xenograft Model Antitumor Assays	2010
Differential interactions between statins and P-glycoprotein: implications for exploiting statins as anticancer agents. International journal of cancer, 2010, Dec-15, Volume: 127, Issue:12 Topics: Antineoplastic Agents; Apoptosis; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Cell Proliferation; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Fatty Acids, Monounsaturated; Female; Fluorobenzenes; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Ovarian Neoplasms; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Tumor Cells, Cultured	2010
Experimental therapy of ovarian cancer with synthetic makaluvamine analog: in vitro and in vivo anticancer activity and molecular mechanisms of action. PloS one, 2011, Volume: 6, Issue:6 Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Cell Line, Tumor; Dose-Response Relationship, Drug; Female; Humans; Membrane Potential, Mitochondrial; Mice; Ovarian Neoplasms; Pyrroles; Quinolones; Signal Transduction; Xenograft Model Antitumor Assays	2011
Identification of novel therapeutic targets in microdissected clear cell ovarian cancers. PloS one, 2011, Volume: 6, Issue:7 Topics: Animals; Cell Death; Cell Hypoxia; Cell Line, Tumor; Cell Survival; Disease Progression; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genome, Human; Glucose; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Mice; Mice, Nude; Microdissection; Microvessels; Molecular Targeted Therapy; Necrosis; Ovarian Neoplasms; Pyrroles; RNA, Small Interfering; Signal Transduction; Sunitinib; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays	2011
RhoB mediates antitumor synergy of combined ixabepilone and sunitinib in human ovarian serous cancer. Gynecologic oncology, 2012, Volume: 124, Issue:3 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Ovarian Epithelial; Cell Growth Processes; Cell Line, Tumor; Cystadenocarcinoma, Serous; Dose-Response Relationship, Drug; Drug Synergism; Epothilones; Female; Humans; Indoles; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Pyrroles; rhoB GTP-Binding Protein; Sunitinib; Up-Regulation	2012
Acute renal failure: a rare side effect of sunitinib therapy. Medical oncology (Northwood, London, England), 2012, Volume: 29, Issue:5 Topics: Acute Kidney Injury; Adenocarcinoma, Clear Cell; Aged; Antineoplastic Agents; Female; Humans; Indoles; Ovarian Neoplasms; Pyrroles; Sunitinib	2012
Structural and molecular docking studies of 4-benzyl-3-[(1-methylpyrrol- 2-yl)methyl]-4,5-dihydro-1H-1,2,4-triazol-5-one with anticancer activity. Medicinal chemistry (Shariqah (United Arab Emirates)), 2013, Volume: 9, Issue:3 Topics: Antineoplastic Agents; Binding Sites; Cell Line; Cell Line, Tumor; Crystallography, X-Ray; Female; Humans; Isomerism; Molecular Docking Simulation; Molecular Structure; Ovarian Neoplasms; Pyrroles; Triazoles	2013
Synthesis of novel C2-aryl pyrrolobenzodiazepines (PBDs) as potential antitumour agents. Chemical communications (Cambridge, England), 2002, Aug-21, Issue:16 Topics: Antineoplastic Agents; Benzodiazepines; Cell Division; Drug Screening Assays, Antitumor; Female; Humans; Male; Melanoma; Ovarian Neoplasms; Pyrroles; Structure-Activity Relationship; Tumor Cells, Cultured	2002
Effective treatment of experimental ES-2 human ovarian cancers with a cytotoxic analog of luteinizing hormone-releasing hormone AN-207. Anti-cancer drugs, 2002, Volume: 13, Issue:9 Topics: Animals; Antineoplastic Agents; Doxorubicin; Drug Evaluation, Preclinical; ErbB Receptors; Female; Gonadotropin-Releasing Hormone; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Pyrroles; Receptor, ErbB-2; Receptors, LHRH; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Treatment Outcome; Tumor Cells, Cultured	2002
SU5416 sensitizes ovarian cancer cells to cisplatin through inhibition of nucleotide excision repair. Cellular and molecular life sciences : CMLS, 2003, Volume: 60, Issue:4 Topics: Carcinoma; Cisplatin; DNA Damage; DNA Repair; DNA-Binding Proteins; Endonucleases; Enzyme Inhibitors; Female; Humans; In Vitro Techniques; Indoles; Mitogen-Activated Protein Kinase 8; Mitogen-Activated Protein Kinases; Ovarian Neoplasms; Proteins; Proto-Oncogene Proteins c-jun; Pyrroles; Transcription Factor AP-1; Tumor Cells, Cultured	2003
The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically. Clinical cancer research : an official journal of the American Association for Cancer Research, 2003, Aug-15, Volume: 9, Issue:9 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Enzyme Inhibitors; Female; Humans; Indoles; Mice; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Oxindoles; Paclitaxel; Propionates; Protein-Tyrosine Kinases; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Platelet-Derived Growth Factor beta; Receptors, Fibroblast Growth Factor; Time Factors; Vascular Endothelial Growth Factor Receptor-2	2003
Mechanisms underlying the synergistic effect of SU5416 and cisplatin on cytotoxicity in human ovarian tumor cells. International journal of oncology, 2004, Volume: 25, Issue:2 Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Apoptosis; Cell Cycle Proteins; Cell Line; Cisplatin; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Drug Synergism; Female; Humans; I-kappa B Proteins; Indoles; JNK Mitogen-Activated Protein Kinases; MAP Kinase Kinase 4; Mitogen-Activated Protein Kinase Kinases; NF-KappaB Inhibitor alpha; Ovarian Neoplasms; Proto-Oncogene Proteins; Pyrroles; Transcription Factor AP-1; Tumor Suppressor Protein p53; Tumor Suppressor Proteins; Up-Regulation	2004
SU5416 inhibited VEGF and HIF-1alpha expression through the PI3K/AKT/p70S6K1 signaling pathway. Biochemical and biophysical research communications, 2004, Nov-12, Volume: 324, Issue:2 Topics: Binding Sites; Blotting, Northern; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Immunoblotting; Indoles; Luciferases; Neovascularization, Pathologic; Ovarian Neoplasms; Phosphatidylinositol 3-Kinases; Phosphorylation; Plasmids; Protein Binding; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Pyrroles; Ribosomal Protein S6 Kinases, 70-kDa; RNA; RNA, Messenger; Signal Transduction; Tetrazolium Salts; Thiazoles; Time Factors; Transcription Factors; Transcriptional Activation; Transfection; Up-Regulation; Vascular Endothelial Growth Factor A	2004
Inhibition of peritoneal dissemination of ovarian cancer by tyrosine kinase receptor inhibitor SU6668 (TSU-68). International journal of cancer, 2005, Mar-20, Volume: 114, Issue:2 Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Line, Tumor; Enzyme Inhibitors; Female; Humans; Indoles; Mice; Mice, Nude; Neoplasm Metastasis; Ovarian Neoplasms; Oxindoles; Platelet-Derived Growth Factor; Propionates; Protein-Tyrosine Kinases; Pyrroles; Survival Analysis; Transplantation, Heterologous; Vascular Endothelial Growth Factor A	2005
Insulin-like growth factor receptor I targeting in epithelial ovarian cancer. Gynecologic oncology, 2006, Volume: 100, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Growth Processes; Cell Line, Tumor; Cisplatin; Dose-Response Relationship, Drug; Drug Synergism; Epithelial Cells; Female; Humans; Insulin-Like Growth Factor I; Insulin-Like Growth Factor II; Ovarian Neoplasms; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyrimidines; Pyrroles; Receptor, IGF Type 1	2006
Kinesin spindle protein (KSP) inhibitors. Part 2: the design, synthesis, and characterization of 2,4-diaryl-2,5-dihydropyrrole inhibitors of the mitotic kinesin KSP. Bioorganic & medicinal chemistry letters, 2006, Apr-01, Volume: 16, Issue:7 Topics: Cell Line, Tumor; Female; Humans; Kinesins; Models, Molecular; Ovarian Neoplasms; Pyrroles; Spindle Apparatus	2006
Modulation of angiogenic phenotype alters tumorigenicity in rat ovarian epithelial cells. Cancer research, 2007, Apr-15, Volume: 67, Issue:8 Topics: Angiogenesis Inhibitors; Animals; Cell Growth Processes; Cell Transformation, Neoplastic; Endostatins; Female; Indoles; Neovascularization, Pathologic; Ovarian Neoplasms; Pyrroles; Rats; Transfection; Vascular Endothelial Growth Factor A	2007
Should tumor VEGF expression influence decisions on combining low-dose chemotherapy with antiangiogenic therapy? Preclinical modeling in ovarian cancer. Journal of translational medicine, 2008, Jan-08, Volume: 6 Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Dose-Response Relationship, Drug; Female; Humans; Indoles; Maximum Tolerated Dose; Mice; Mice, Inbred C57BL; Microcirculation; Ovarian Neoplasms; Paclitaxel; Pyrroles; Recombinant Proteins; Vascular Endothelial Growth Factor A	2008
Fluorescent 7-diethylaminocoumarin pyrrolobenzodiazepine conjugates: synthesis, DNA interaction, cytotoxicity and differential cellular localization. Bioorganic & medicinal chemistry letters, 2008, Mar-15, Volume: 18, Issue:6 Topics: Benzodiazepines; Cell Nucleus; Cell Survival; Cytoplasm; DNA; Female; Humans; Melanoma; Microscopy, Fluorescence; Molecular Structure; Ovarian Neoplasms; Pyrroles; Tumor Cells, Cultured	2008
Makaluvamines, marine natural products, are active anti-cancer agents and DNA topo II inhibitors. Anti-cancer drug design, 1993, Volume: 8, Issue:5 Topics: Animals; Antineoplastic Agents; CHO Cells; Colonic Neoplasms; Cricetinae; Drug Screening Assays, Antitumor; Female; Humans; Leukemia, Experimental; Mice; Mice, Inbred BALB C; Mice, Inbred Strains; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Porifera; Pyrroles; Quinones; Topoisomerase II Inhibitors; Tumor Cells, Cultured	1993
Effect of C2-exo unsaturation on the cytotoxicity and DNA-binding reactivity of pyrrolo[2,1-c][1,4]benzodiazepines. Bioorganic & medicinal chemistry letters, 2000, Aug-21, Volume: 10, Issue:16 Topics: Animals; Antibiotics, Antineoplastic; Benzodiazepines; Benzodiazepinones; DNA; Drug Screening Assays, Antitumor; Female; Humans; Molecular Structure; Ovarian Neoplasms; Pyrroles; Tumor Cells, Cultured	2000
Effect of C2/C3-endo unsaturation on the cytotoxicity and DNA-binding reactivity of pyrrolo[2,1-c][1,4]benzodiazepines. Bioorganic & medicinal chemistry letters, 2000, Aug-21, Volume: 10, Issue:16 Topics: Anthramycin; Antibiotics, Antineoplastic; Benzodiazepines; Chemistry, Organic; DNA; Drug Screening Assays, Antitumor; Female; Humans; Molecular Structure; Organic Chemistry Phenomena; Ovarian Neoplasms; Pyrroles; Tumor Cells, Cultured	2000
Inhibition of the UCI-107 human ovarian carcinoma cell line by a targeted cytotoxic analog of somatostatin, AN-238. Cancer, 2001, Sep-01, Volume: 92, Issue:5 Topics: Animals; Antibiotics, Antineoplastic; Carboxylic Ester Hydrolases; Doxorubicin; Drug Screening Assays, Antitumor; Female; Humans; Mice; Mice, Nude; Microsatellite Repeats; Ovarian Neoplasms; Pyrroles; Radioligand Assay; Receptors, Somatostatin; Reverse Transcriptase Polymerase Chain Reaction; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2001
Brostallicin, a novel anticancer agent whose activity is enhanced upon binding to glutathione. Cancer research, 2002, Apr-15, Volume: 62, Issue:8 Topics: Animals; Antineoplastic Agents; Drug Synergism; Female; Glutathione; Glutathione S-Transferase pi; Glutathione Transferase; Guanidines; Humans; Isoenzymes; Leukemia L1210; Mice; Mice, Nude; Ovarian Neoplasms; Plasmids; Pyrroles; Transfection; Tumor Cells, Cultured	2002
Structure-activity studies of antitumor agents based on pyrrolo[1,2-a]benzimidazoles: new reductive alkylating DNA cleaving agents. Journal of medicinal chemistry, 1991, Volume: 34, Issue:10 Topics: Alkylation; Antineoplastic Agents; Aziridines; Benzimidazoles; Colonic Neoplasms; DNA; Female; Free Radicals; Humans; Molecular Structure; Multiple Myeloma; Ovarian Neoplasms; Oxidation-Reduction; Oxygen; Pyrroles; Structure-Activity Relationship; Tumor Cells, Cultured	1991